SLC9A1 and breast cancer: Pharmacological inhibition of NHE1 using EIPA or cariporide sensitizes p95HER2-expressing MCF-7 human breast cancer cells grown in 2D culture to cisplatin (a purine crosslinker, which has an effect similar to that of DNA-alkylating agents) chemotherapy31,32.